SEC Tracker
Get the app
RNTX · XBRL financial data

Rein Therapeutics financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal years (RNTX's year ends in late December)

In thousands of dollarsDec 31, 2020Dec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025
Revenue from contracts with customers000000
Research and development11,16617,00817,9673,99114,24811,029
General and administrative9,3309,5979,68011,35713,86410,902
Total operating expenses20,49626,60527,64716,27665,11250,631
Operating income (loss)(20,496)(26,605)(27,647)(16,276)(65,112)(50,631)
Other income (expense)(661)44131854468548
Income tax expense (benefit)0000(1,544)(712)
Net income (loss)(21,157)(26,164)(27,329)(15,732)(62,883)(49,871)
Earnings per share, basic USD per share—(5.89)(6.02)(3.42)(3.51)(1.96)
Earnings per share, diluted USD per share—(5.89)(6.02)(3.42)(3.51)(1.96)
Weighted average shares, basic thousands of shares—4,4404,5394,59917,93925,445
Weighted average shares, diluted thousands of shares—4,4404,5394,59917,93925,445

Balance sheet

CSV

Fiscal years (RNTX's year ends in late December)

In thousands of dollarsDec 31, 2020Dec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025
Cash and cash equivalents7,0463,6005,19417,31312,8653,215
Short-term investments—————0
Marketable securities6,75942,33316,048———
Prepaid and other current assets1,9282,2196068827921,111
Total current assets16,32648,17721,87318,26613,6574,326
Property and equipment, net15128701910
Right-of-use asset—15240———
Goodwill———6,3306,3306,330
Total assets16,34148,48122,007106,00862,19024,158
Accounts payable1,5961,2101,7201,1909113,976
Total current liabilities3,9604,5083,3844,3855,7496,180
Lease liability, non-current—69————
Total liabilities4,1794,5773,3847,7117,7987,240
Accumulated deficit(219,292)(245,456)(272,785)(288,517)(351,400)(401,271)
Total stockholders' equity12,16243,90418,6236,88754,39216,918
Total liabilities and equity16,34148,48122,007106,00862,19024,158
Common shares outstanding (cover page)‡ thousands of shares4,5114,5294,54116,97321,99228,039
  • ‡ Per-share figures and share counts are adjusted for the 1-for-20 stock split (November 2022); filings made before it reported them unadjusted.

Cash flows

CSV

Fiscal years (RNTX's year ends in late December)

In thousands of dollarsDec 31, 2020Dec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025
Net income (loss)(21,157)(26,164)(27,329)(15,732)(62,883)(49,871)
Stock-based compensation1,8932,2602,0831,1901,1172,224
Depreciation and amortization163121169119631
Net cash from operating activities(20,476)(23,754)(24,865)(19,808)(22,291)(19,361)
Purchases of property and equipment5157————
Net cash from investing activities6,411(35,917)26,45916,1960—
Proceeds from issuing common stock16,881——010,6451,819
Proceeds from issuing equity1,801—————
Net cash from financing activities15,80055,657—15,79417,8189,755
Net change in cash1,735(4,014)1,59412,119(4,473)(9,650)

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Rein Therapeutics8,5420(8,640)*86.3M4.7 quarters 10-QJun 30, 2026
Insight Molecular Diagnostics17,756239(9,268)*32.7M1.9 quarters 10-QJun 30, 2026
Yarrow Bioscience22,92597(1,992)*2.7M11.5 quarters 10-QJun 30, 2026
Kezar Life Sciences66,229not reported(7,445)7.4M8.9 quarters 10-QMar 31, 2026
Provectus Biopharmaceuticals1,157not reported(358)*420.3M3.2 quarters 10-QJun 30, 2026
Tempest Therapeutics779not reported(2,779)*16.0M0.3 quarters 10-QJun 30, 2026
ProMIS Neurosciences53,429not reported(10,385)*9.0M5.1 quarters 10-QJun 30, 2026
Grace Therapeutics13,756not reported(3,221)21.0M4.3 quarters 10-QJun 30, 2026
Cumberland Pharmaceuticals3,862166169*15.0M— 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.